Richard Moulson
Plus aucun poste en cours
Fortune : 405 $ au 31/05/2024
Profil
Richard Moulson served as Chief Financial Officer & Director at Evgen Pharma Plc, Chief Financial Officer at ReNeuron Group Plc, Chief Financial Officer & Secretary at Regenerative Medicine Assets Ltd., and Chief Financial Officer at Sterecycle (Rotherham) Ltd.
He also served as Chief Financial Officer at Intercytex Ltd.
from 2002 to 2006.
Moulson received his undergraduate degree from The University of Exeter.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
THERACRYF PLC
0,01% | 31/03/2023 | 45 454 ( 0,01% ) | 405 $ | 31/05/2024 |
Anciens postes connus de Richard Moulson
| Sociétés | Poste | Fin |
|---|---|---|
Sterecycle (Rotherham) Ltd.
 Sterecycle (Rotherham) Ltd. Environmental ServicesIndustrial Services Sterecycle is a waste management business focused on recycling and green energy. It has its own patented technologies that are capable of recycling and recovering the typical household waste stream. Since June 2008 it has been operating a full scale plant in Yorkshire. This is the World's 1st full scale commercial autoclave plant to treat residual household waste. The plant is processing 'black-bag' waste from 3 local authorities under a contract for up to 10 years: Rotherham Metropolitan Borough Council, Barnsley Metropolitan Borough Council and Doncaster Metropolitan Borough Council. Whilst autoclaving has been used for a number of years for sterilizing small batches of medical waste, it has pioneered its use at industrial scale and for recycling municipal solid waste. In addition, the facility uses its own unique autoclaving system which is highly energy efficient and integrated with a green energy plant is self-sustaining with a beneficial carbon footprint. Its technology is protected by a series of granted patents and patent applications. Its business model is to build, own and operate waste recycling plants, processing residual waste as a substitute for landfill. It is a well funded business, backed by blue chip investors including Goldman Sachs, Fidelity International and Impax Asset Management. | Directeur Financier/CFO | 06/05/2014 |
Regenerative Medicine Assets Ltd.
 Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Directeur Financier/CFO | 16/09/2008 |
Intercytex Ltd.
 Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds. | Directeur Financier/CFO | 03/02/2006 |
| THERACRYF PLC | Directeur Financier/CFO | - |
| RENEURON GROUP PLC | Directeur Financier/CFO | 23/04/2014 |
Formation de Richard Moulson
| The University of Exeter | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RENEURON GROUP PLC | Health Technology |
| THERACRYF PLC | Health Services |
| Entreprise privées | 3 |
|---|---|
Regenerative Medicine Assets Ltd.
Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
Intercytex Ltd.
Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds. | Health Technology |
Sterecycle (Rotherham) Ltd.
Sterecycle (Rotherham) Ltd. Environmental ServicesIndustrial Services Sterecycle is a waste management business focused on recycling and green energy. It has its own patented technologies that are capable of recycling and recovering the typical household waste stream. Since June 2008 it has been operating a full scale plant in Yorkshire. This is the World's 1st full scale commercial autoclave plant to treat residual household waste. The plant is processing 'black-bag' waste from 3 local authorities under a contract for up to 10 years: Rotherham Metropolitan Borough Council, Barnsley Metropolitan Borough Council and Doncaster Metropolitan Borough Council. Whilst autoclaving has been used for a number of years for sterilizing small batches of medical waste, it has pioneered its use at industrial scale and for recycling municipal solid waste. In addition, the facility uses its own unique autoclaving system which is highly energy efficient and integrated with a green energy plant is self-sustaining with a beneficial carbon footprint. Its technology is protected by a series of granted patents and patent applications. Its business model is to build, own and operate waste recycling plants, processing residual waste as a substitute for landfill. It is a well funded business, backed by blue chip investors including Goldman Sachs, Fidelity International and Impax Asset Management. | Industrial Services |
